In a political landscape where financial backing often sparks debate, Washington state Sen. John Braun’s campaign contributions from the pharmaceutical and health insurance industries have drawn attention. These contributions coincide with his voting record, which includes opposing measures aimed at making health care more affordable.
Currently, Braun is campaigning for a seat in the U.S. House representing Washington’s 3rd District, a position held by Democratic Rep. Marie Gluesenkamp Perez.
Analysis of campaign finance records reveals that Braun has received $73,550 from pharmaceutical companies and $37,400 from the health insurance sector since 2012. These contributions account for approximately 10% of his total campaign donations.
In 2022, Braun opposed a bipartisan initiative to create Washington’s Prescription Drug Affordability Board, which is designed to assess drug costs and implement payment caps for consumers and insurers. The AARP has endorsed the board, stating it “could lead to lower insurance premiums, reduce taxpayer spending on health care, and would help ensure people can afford the medication they need.” However, PhRMA, a pharmaceutical trade group that contributed to Braun’s campaign in 2015 and 2016, has criticized such affordability boards.
The previous year, Braun voted against a bill that would have allowed the state to purchase, produce, and distribute generic drugs as a cost-effective alternative to brand-name medications. In 2020, Braun also opposed legislation enabling Washington to bulk-purchase insulin and offer it at reduced rates, as well as a bill mandating health insurance coverage for pre-existing conditions.
Despite these stances, Braun asserts that his primary focus is on affordability and cost reduction. In a June statement, he criticized Gluesenkamp Perez for her opposition to “the largest tax cut in history,” although this tax cut primarily benefits wealthier individuals while cutting Medicaid by $1 trillion.
As the 2026 election approaches, health care costs are likely to be a significant concern. A June 2026 Gallup poll indicated that Americans’ capacity to afford health care has reached a five-year low.
Braun’s campaign has secured an endorsement from President Donald Trump.
The post Braun took drug industry money, opposed lower health care costs appeared first on American Journal News.
